FINASTERIDE AND TADALAFIL Drug Patent Profile
✉ Email this page to a colleague
When do Finasteride And Tadalafil patents expire, and when can generic versions of Finasteride And Tadalafil launch?
Finasteride And Tadalafil is a drug marketed by Zydus Lifesciences and is included in one NDA.
The generic ingredient in FINASTERIDE AND TADALAFIL is finasteride; tadalafil. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the finasteride; tadalafil profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FINASTERIDE AND TADALAFIL?
- What are the global sales for FINASTERIDE AND TADALAFIL?
- What is Average Wholesale Price for FINASTERIDE AND TADALAFIL?
Summary for FINASTERIDE AND TADALAFIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 2 |
| DailyMed Link: | FINASTERIDE AND TADALAFIL at DailyMed |
Recent Clinical Trials for FINASTERIDE AND TADALAFIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vanderbilt University Medical Center | Phase 2 |
| Eli Lilly and Company | Phase 3 |
US Patents and Regulatory Information for FINASTERIDE AND TADALAFIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences | FINASTERIDE AND TADALAFIL | finasteride; tadalafil | CAPSULE;ORAL | 218232-001 | Mar 15, 2024 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
